KeyCorp Upgrades GoodRx (NASDAQ:GDRX) to Overweight

KeyCorp upgraded shares of GoodRx (NASDAQ:GDRX - Free Report) from a sector weight rating to an overweight rating in a report published on Wednesday morning, Marketbeat reports. The firm currently has $9.00 price target on the stock.

A number of other brokerages also recently issued reports on GDRX. SVB Leerink assumed coverage on shares of GoodRx in a research note on Monday, February 26th. They set an outperform rating and a $8.00 price objective on the stock. Bank of America downgraded shares of GoodRx from a buy rating to an underperform rating and reduced their price objective for the stock from $8.00 to $4.50 in a research note on Tuesday, January 2nd. Truist Financial increased their price objective on shares of GoodRx from $7.50 to $8.00 and gave the stock a hold rating in a research note on Friday, March 1st. The Goldman Sachs Group raised their price target on shares of GoodRx from $6.50 to $7.50 and gave the company a neutral rating in a research note on Friday, March 1st. Finally, UBS Group raised their price target on shares of GoodRx from $5.00 to $8.00 and gave the company a neutral rating in a research note on Friday, March 1st. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of Hold and a consensus target price of $8.78.

GoodRx Stock Up 3.9 %

GDRX traded up $0.26 during trading hours on Wednesday, hitting $7.00. 1,543,220 shares of the company's stock were exchanged, compared to its average volume of 1,618,561. GoodRx has a 1-year low of $4.14 and a 1-year high of $9.37. The stock's 50-day moving average is $6.81 and its two-hundred day moving average is $6.15. The stock has a market cap of $2.77 billion, a price-to-earnings ratio of -336.83, a PEG ratio of 3.75 and a beta of 1.42. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.85.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings data on Thursday, February 29th. The company reported $0.02 earnings per share for the quarter, meeting the consensus estimate of $0.02. The company had revenue of $196.64 million for the quarter, compared to analyst estimates of $195.59 million. GoodRx had a negative net margin of 1.18% and a positive return on equity of 2.45%. Sell-side analysts predict that GoodRx will post 0.23 earnings per share for the current fiscal year.

Institutional Trading of GoodRx

Hedge funds have recently modified their holdings of the stock. Tower Research Capital LLC TRC increased its stake in shares of GoodRx by 2,602.7% in the 3rd quarter. Tower Research Capital LLC TRC now owns 6,919 shares of the company's stock valued at $39,000 after acquiring an additional 6,663 shares in the last quarter. Citigroup Inc. grew its position in GoodRx by 301.7% in the 3rd quarter. Citigroup Inc. now owns 7,997 shares of the company's stock valued at $45,000 after purchasing an additional 6,006 shares during the period. Ensign Peak Advisors Inc acquired a new stake in GoodRx in the 3rd quarter valued at $42,000. Delphia USA Inc. acquired a new stake in GoodRx in the 1st quarter valued at $199,000. Finally, Creative Planning acquired a new stake in GoodRx in the 4th quarter valued at $50,000. Institutional investors own 63.77% of the company's stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.